Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/second-multi-target-collaboration-with-ucb-announced-5026